Causaly, the leading AI platform for biomedical research, closed $60m in Series B funding led by ICONIQ Growth, with participation from Index Ventures
AI is changing medicine getty
There has been much discussion recently about how artificial intelligence and machine learning (AI/ML) will revolutionize pharmaceutical research. Substantial progress has been made in the discovery and identification of new drugs enabled by AL/ML. Now the clinical testing process is being revitalized by advances in technology. The US Food and Drug…
Text size
…
Sanofi is jumping on the artificial intelligence boat with a new app and a pledge to become “the first pharma company powered by artificial intelligence at scale.” | Sanofi's new app, plai, provides teams with a “360° view" to aid decision-making. The platform is one step in the company's digital transformation and goal to become…
Company Logo Dublin, June 09, 2023 (GLOBE NEWSWIRE) -- The "Red Biotechnology Market Size, Share & Trends Analysis Report By Product, By End-user (Academic Research Institutes, CMOs & CROs, Pharmaceutical & Biotechnology Companies, Others), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering. The global red biotechnology market…
With generative artificial intelligence (AI) seemingly gaining traction by the day, more market participants are evaluating where this innovation fits into their industries. Biotech may be next for disruption.
The biotech sector has a long history of innovation, intersecting with disruptive technologies in the pursuit of new therapies and treatments. AI may be next to…
Recursion has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica, for $40 million, and Valence, for $47.5 million. Chris Gibson, co-founder and CEO of Salt Lake City headquartered Recursion, said: “Recursion has pioneered the massive, parallel generation of -omics data with machine learning in order to map and navigate biology…
Moderna is planning to incorporate quantum computing and artificial intelligence into its mRNA drug discovery engine — plus more, from the Petri Dish.
Regeneron Pharmaceuticals (REGN) said on Monday that its Q1 acquired in-process research and development charges will be ~$56M on a pretax basis.
Regeneron isn’t the only company eager to derive more value from its data. Despite the enormous amounts of data they collect and the amount of capital they invest in data management solutions, business leaders are still not benefitting from their data. According to IDC research, 83% of CEOs want their organizations to be more data…
Text size
…
Charlotte Deane, PhD, MBE, Exscientia Chief Scientist of Biologics AI and Professor of Structural Bioinformatics at University of Oxford.
After spending the past decade pioneering the use of artificial intelligence (AI) toward designing small molecule drugs, Exscientia has expanded its AI-based platform to begin designing precision engineered and optimized, fully human biologics, starting with novel antibodies.
The…